– USA, CA – Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, today announced the appointment of Dr. Robert Booth to its Board of Directors.
About Dr. Robert Booth
Dr. Robert Booth, distinguished for his invaluable contributions to the biopharmaceutical industry, brings over 30 years of experience in drug discovery, development, and executive leadership. Dr. Booth earned his Ph.D. in biochemistry from University College London and rose to SVP at F. Hoffmann-La Roche AG early in his career. As CSO at Celera Genomics, Dr. Booth initiated the BTK inhibitor program that led to the development of Imbruvica, a revolutionary treatment for many hematological cancers. This groundbreaking inhibitor was later licensed to Pharmacyclics, where Dr. Booth served on the Board of Directors until its acquisition by AbbVie.
Within academia, Dr. Booth has been an adjunct professor at Stanford University School of Medicine where his work led him to co-found CuraSen Therapeutics, Inc. He also served as the founder and CEO of Virobay Inc. and was an instrumental operating partner and senior advisor at TPG Biotech. He presently serves on the boards of Thryv Therapeutics and Summit Therapeutics, bringing his industry expertise to provide strategic direction.
About Acurex Biosciences:
Acurex was co-founded by a distinguished team of experts, including accomplished drug developer Dr. William Shrader, Stanford Professor Dr. Xinnan Wang, and successful life-science entrepreneurs Lev and Galina Leytes. Acurex has secured over $18M in private and grant seed funding, with substantial contributions from Stanford University, the Silverstein Foundation, the Michael J. Fox Foundation, and the NIH. Acurex is raising its Series A to finance the continued development of its biomarker and advancement of its therapeutic programs into initial human clinical trials.
For more information: https://www.acurex.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.